Get the tools used by (smart)2 investors.

Diluted EPS Incl Extra Items for Inozyme Pharma Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

INZY: Inozyme Pharma Inc

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...

1.00 USD
Price
USD
Fair Value
Upside
0.98 - 7.79
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Inozyme Pharma Inc's Diluted EPS Incl Extra Items:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-20-15-10-50

Performance Summary
  • Inozyme Pharma Inc's latest twelve months diluted eps incl extra items is -1.62
  • Inozyme Pharma Inc's diluted eps incl extra items for fiscal years ending December 2020 to 2024 averaged -2.46.
  • Inozyme Pharma Inc's operated at median diluted eps incl extra items of -1.78 from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Inozyme Pharma Inc's diluted eps incl extra items peaked in December 2023 at -1.37.
  • Inozyme Pharma Inc's diluted eps incl extra items hit its 5-year low in December 2020 of -5.11.
  • Inozyme Pharma Inc's diluted eps incl extra items decreased in 2024 (-1.62, +18.3%) and increased in 2020 (-5.11, -69.3%), 2021 (-2.40, -53.0%), 2022 (-1.78, -26.1%), and 2023 (-1.37, -22.7%).

How does Inozyme's Diluted EPS Incl Extra Items benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: Diluted EPS Incl Extra Items

Hide this widget
eps_diluted
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM, YTD
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Diluted EPS Incl Extra Items in the financials category include:

  • EBT Excl. Unusual Items - This item represents EBT Before Non Recurring Items and is arrived at after adjusting, the following, to Operating Profit (OPIN): 1. Interest Expense, Total and 2. Total Non Operating Income/(Expenses) (NOIET).
  • Net Income to Stockholders - This item represents the net income or loss available to preferred and common stockholders and is arrived after adjusting net income to the company.
  • Issuance of Common Stock - The amount of cash received by the company from issuing company stock in the given period.
  • Stock-Based Comp, SG&A Expense - This item represents the stock based compensation included in SG&A when available.
View Full List

Search for metric or datapoint

Diluted EPS Incl Extra Items

Company's net earnings or losses from continuing operations adjusted for certain one-time items on a per diluted share basis.

Definition of Diluted EPS Incl Extra Items

Hide this widget

Inozyme Pharma reported diluted eps of -1.62 for the latest twelve months ending December 31, 2024 on its income statement.

Diluted EPS Incl Extra Items measures the amount of earnings per outstanding share of common stock for a company.

Basic Net Income = Net Income - Preferred Dividends
Diluted EPS = Basic Net Income  / Diluted Shares Outstanding

Diluted EPS differs from Basic EPS. Basic EPS does not take into account the impact of dilutive securities like stock options or convertible bonds that a company may have in its financing structure

Read more about [basic eps incl extra items](https://finbox.com/NASDAQGM:INZY/explorer/eps_basic)

The tables below summarises Inozyme Pharma’s diluted eps over the last five years:

Fiscal Year Diluted EPS
2020-12-31 -5.11
2021-12-31 -2.40
2022-12-31 -1.78
2023-12-31 -1.37
2024-12-31 -1.62

The tables below summarizes Inozyme Pharma’s diluted eps over the last four quarters:

Quarter Ending Diluted EPS
2024-03-31 -0.38
2024-06-30 -0.44
2024-09-30 -0.39
2024-12-31 -0.42

Click the link below to download a spreadsheet with an example Diluted EPS Incl Extra Items calculation for Inozyme Pharma Inc below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-36.92-21.92-6.928.312006001,000

The chart above depicts the distribution of diluted eps incl extra items for companies operating in the Healthcare sector in the Developed economic region. Over 2,470 companies were considered in this analysis, and 2,376 had meaningful values. The average diluted eps incl extra items of companies in the sector is -1.23 with a standard deviation of 4.27.

Inozyme Pharma Inc's Diluted EPS Incl Extra Items of -1.62 ranks in the 20.5% percentile for the sector. The following table provides additional summary stats:

Diluted EPS Incl Extra Items In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,474
Included Constituents2,376
Min-38.52
Max7.56
Median-0.11
Mean-1.23
Standard Deviation4.27

You can find companies with similar diluted eps incl extra items using this stock screener.

All rights reserved. Terms Of Use